Approximately 86 subjects will be randomized 1:1 to receive either monthly intradermal Vigil or placebo for at least 4 to a maximum of 12 administrations. Randomization will be stratified by (i) extent of surgical cytoreduction (complete/microscopic versus macroscopic residual disease) and (ii) neoadjuvant versus adjuvant chemotherapy. The primary objective is determining RFS of subjects randomized to Vigil versus placebo, and the key secondary objective is overall survival (OS) of subjects randomized to Vigil versus placebo.